Clinical Trials Logo

Clinical Trial Summary

The purpose of this general screening protocol is to facilitate recruitment into studies conducted at the Center for Virology and Vaccine Research (CVVR) or Division of Infectious Diseases at Beth Israel Deaconess Medical Center. This general screening protocol will help to determine the eligibility of potential volunteers for any vaccine or therapeutic trials open for recruitment or soon to be opened.


Clinical Trial Description

The purpose of this general screening protocol is to facilitate recruitment into studies conducted at the Center for Virology and Vaccine Research (CVVR) and Division of Infectious Diseases at Beth Israel Deaconess Medical Center. This protocol will help us to determine whether a volunteer is eligible for completing the screening process and which protocols might best be suited to the participant. Volunteers will be adults interested in participating in a clinical trial, such as a vaccine or therapeutic study, and particularly for studies conducted as part of the HIV Vaccine Trials Network. Occasionally, the screening protocol may be used for an observational study. This general screening protocol will help to determine the eligibility of potential volunteers for any clinical trials open for recruitment or soon to be opened. No investigational products will be administered under this protocol. All main vaccine or intervention studies will be submitted as separate applications to the appropriate regulatory agency as required by the sponsor. Prescreening of volunteers may be done via telephone using an already approved script and RedCap questionnaire. Following the prescreening, the volunteer will be scheduled for an in-person clinic visit with a study clinician (MD, NP or RN). All participants in this study will be screened for safety, including a physical exam, vital signs and laboratory testing. This is to ensure that participants meet the appropriate inclusion and exclusion criteria related to safety in a clinical trial. The following study procedures will be performed at the Clinical Research Center at BIDMC: 1. Informed Consent process completed before any other study activities are conducted 2. Demographics 3. Medical history 4. Review of current medications 5. Targeted physical exam including vital signs 6. Behavioral risk assessment to determine risk of acquiring HIV 7. Contraception status 8. Blood or urine collection: on average, most safety screening laboratory tests will require no more than 60mL of blood which will be resulted in BIDMC's clinical laboratory. A urine sample may be collected for people of childbearing potential to determine pregnancy status. Laboratory tests will be checked against eligibility criteria of open or soon-to-be opened clinical trials. If a test or exam result suggest that further medical evaluation or treatment may be necessary, the participant will be notified and referred to their care provider for further treatment. A copy of test results will be provided if requested. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06463704
Study type Observational [Patient Registry]
Source Beth Israel Deaconess Medical Center
Contact Kathryn E Stephenson, MD, MPH
Phone 617-735-4556
Email kstephen@bidmc.harvard.edu
Status Not yet recruiting
Phase
Start date June 2024
Completion date June 2034

See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1